ReviewNature reviews. Gastroenterology & hepatology2022
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.
Review in Nature reviews. Gastroenterology & hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05738746 (The Effects of the Anti-inflammatory Microbe - Pasteurized Akkermansia Muciniphila), which is not on this map. Cited by 654 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effects of the Anti-inflammatory Microbe - Pasteurized Akkermansia Muciniphila (PAM) on Symptoms of Somatic and Mental Stress in Healthcare Professionals
Who cites it
654 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,024 citations in OpenAlex.
- Unravelling the role of the gut microbiome in antipsychotic-induced weight gain and metabolic dysfunction in humans and rodents: A systematic review.Dialogues in clinical neuroscience · 2026Pooled it
- Effect of pasteurizedGut microbes · 2026Trial
- Dietary fibre blend improves gut health in patients with irritable bowel syndrome following a low FODMAP diet: a randomised, double-blind control trial.European journal of nutrition · 2026Trial
- Gut microbiota responses to isocaloric macronutrient modulation in tissue-specific insulin resistance: a secondary analysis of the PERSonalized glucose Optimization through Nutritional intervention (PERSON) randomized trial.The American journal of clinical nutrition · 2026Trial
- AdjuvantMicrobiology spectrum · 2026Trial
- Pasteurized Akkermansia muciniphila MucNature medicine · 2026Trial
- Rectal ozone insufflation modulates gut microbiota: improving lung function in mice with chronic obstructive pulmonary disease.Medical gas research · 2027Article
- Gut microbiota shaping fatty liver disease progression.Life science alliance · 2027Review
- Host metabolism shapes the intestinal microbiota: a top-down paradigm of environmental selection pressure.Gut microbes · 2026Review
- Dysregulated eating behaviour and microbiota-based interventions targeting eating disorders and food addiction.Gut microbes · 2026Review
- Distinction of meal quality and interaction with the gut microbiota by breath volatilome analysis in humans.Gut microbes · 2026Article
- Article
- Zip14 (Slc39a14) metal transporter dysfunction leads toGut microbes · 2026Article
- Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy.Gut microbes · 2026Review
- A 4-guanidinobutanoic acid-SLC36A1 axis drives a microbiota‒host feedback loop to regulate intestinal homeostasis.Gut microbes · 2026Article
- Alcohol consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): understanding the gut-liver crosstalk for clinical translation.Gut microbes · 2026Article
- Article
- Article
- Peptide LKLKLL is a more effective component ofGut microbes · 2026Article
- Article
594 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ever since Akkermansia muciniphila was discovered and characterized two decades ago, numerous studies have shown that the lack or decreased abundance of this commensal bacterium was linked with multiple diseases (such as obesity, diabetes, liver steatosis, inflammation and response to cancer immunotherapies). Although primarily based on simple associations, there are nowadays an increasing number of studies moving from correlations to causality. The causal evidence derived from a variety of animal models performed in different laboratories and recently was also recapitulated in a human proof-of-concept trial. In this Review, we cover the history of the discovery of A. muciniphila and summarize the numerous findings and main mechanisms of action by which this intestinal symbiont improves health. A comparison of this microorganism with other next-generation beneficial microorganisms that are being developed is also made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.